The human Pk histo-blood group antigen provides protection against HIV-1 infection

Blood

Volumn 113, Issue 20, 2009, Pages 4980-4991

  Lund, Nicole ^a,b   Olsson, Martin L ^c   Ramkumar, Stephanie ^a   Sakac, Darinka ^b   Yahalom, Vered ^d   Levene, Cyril ^d   Hellberg, Åsa ^c   Ma, Xue Zhong ^a,b   Binnington, Beth ^e   Jung, Daniel ^f,g   Lingwood, Clifford A ^a,e   Branch, Donald R ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c LUND UNIVERSITY   (Sweden)

^d MAGEN DAVID ADOM   (Israel)

^e HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^f HÉMA QUÉBEC   (Canada)

^g UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD GROUP ANTIGEN; CD4 ANTIGEN; CHEMOKINE RECEPTOR; GANGLIOSIDE GM3; GLUCOSYLCERAMIDE; PK ANTIGEN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CERAMIDE TRIHEXOSIDE; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CXCR4 PROTEIN, HUMAN; GALACTOSYLTRANSFERASE; GLOBOTRIAOSYLCERAMIDE; UDP GALACTOSE GALBETA1 4GLCBETA1 CER ALPHA1,4 GALACTOSYLTRANSFERASE; UDP-GALACTOSE - GALBETA1-4GLCBETA1-CER ALPHA1,4-GALACTOSYLTRANSFERASE;

ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTER; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; THIN LAYER CHROMATOGRAPHY; BLOOD; CELL CULTURE; CELL PROTECTION; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETIC TRANSFECTION; GENETICS; HELA CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; INNATE IMMUNITY; LEUKEMIA CELL LINE; METABOLISM; PHYSIOLOGY;

ANTIGENS, CD4; CELLS, CULTURED; CYTOPROTECTION; GALACTOSYLTRANSFERASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENETIC PREDISPOSITION TO DISEASE; HELA CELLS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, INNATE; JURKAT CELLS; RECEPTORS, CCR5; RECEPTORS, CXCR4; RNA, SMALL INTERFERING; TRANSFECTION; TRIHEXOSYLCERAMIDES;

EID: 66549127485     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-03-143396     Document Type: Article

References (52)

1. Arenzana-Seisdedos F, Parmentier M. Genetics of resistance to HIV infection: role of coreceptors and coreceptor ligands. Semin Immunol. 2006;18:387-403. (Pubitemid 44511884)
2. de Silva E, Stumpf MP. HIV and the CCR5-delta32 resistance allele. FEMS Microbiol Lett. 2004;241:1-12.
3. Paxton WA, Kang S. Chemokine receptor allelic polymorphisms: relationships to HIV resistance and disease progression. Semin Immunol. 1998;10:187-194. (Pubitemid 28347035)
4. Moulds JM, Moulds JJ. Blood group associations with parasites, bacteria, and viruses. Transfus Med Rev. 2000;14:302-311.
5. Spitalnik PF, Spitalnik SL. The P blood group system: biochemical, serological, and clinical aspects. Transfus Med Rev. 1995;9:110-122.
6. Daniels G. Human Blood Groups. Malden, MA: Blackwell Science; 2002.
7. Lingwood CA. Role of verotoxin receptors in pathogenesis. Trends Microbiol. 1996;4:147-153.
8. Schwartz-Albiez R, Dorken B, Moller P, Brodin NT, Monner DA, Kniep B. Neutral glycosphingolipids of the globo-series characterize activation stages corresponding to germinal center B cells. Int Immunol. 1990;2:929-936. (Pubitemid 20330542)
9. Hellberg A, Poole J, Olsson ML. Molecular basis of the globoside-deficient P(k) blood group phenotype. Identification of four inactivating mutations in the UDP-N-acetylgalactosamine: globotriaosylceramide 3-beta-N-acetylgalactosaminyltransferase gene. J Biol Chem. 2002;277:29455- 29459. (Pubitemid 41079230)
10. Hellberg A, Chester MA, Olsson ML. Two previously proposed P1/P2-differentiating and nine novel polymorphisms at the A4GALT (Pk) locus do not correlate with the presence of the P1 blood group antigen. BMC Genet. 2005;6:49. (Pubitemid 41554905)
11. Hellberg A, Ringressi A, Yahalom V, Safwenberg J, Reid ME, Olsson ML. Genetic heterogeneity at the glycosyltransferase loci underlying the GLOB blood group system and collection. Br J Haematol. 2004;125:528-536. (Pubitemid 38916199)
12. Furukawa K, Iwamura K, Uchikawa M, et al. Molecular basis for the p phenotype: identification of distinct and multiple mutations in the alpha 1,4-galactosyltransferase gene in Swedish and Japanese individuals. J Biol Chem. 2000;275:37752-37756. (Pubitemid 32004890)
13. Steffensen R, Carlier K, Wiels J, et al. Cloning and expression of the histo-blood group Pk UDP-galactose: Galpha1beta-4G1cbeta1-cer alpha1, 4-galactosyltransferase. Molecular genetic basis of the p phenotype. J Biol Chem. 2000;275:16723-16729. (Pubitemid 30398903)
14. Hellberg A, Steffensen R, Yahalom V, et al. Additional molecular bases of the clinically important p blood group phenotype. Transfusion. 2003;43:899-907. (Pubitemid 36753940)
15. Mylvaganam M, Lingwood CA. A convenient oxidation of natural glycosphingolipids to their "ceramide acids" for neoglycoconjugation: bovine serum albumin-glycosylceramide acid conjugates as investigative probes for HIV gp120 coat protein-glycosphingolipid interactions. J Biol Chem. 1999;274:20725-20732.
16. Fantini J, Hammache D, Delezay O, Pieroni G, Tamalet C, Yahi N. Sulfatide inhibits HIV-1 entry into CD4 super(-)/CXCR4 super(+) cells. Virology. 1998;246:211-220. (Pubitemid 28384035)
17. Hammache D, Pieroni G, Yahi N, et al. Specific interaction of HIV-1 and HIV-2 surface envelope glycoproteins with monolayers of galactosylceramide and ganglioside GM3. J Biol Chem. 1998;273:7967-7971. (Pubitemid 28168845)
18. Mahfoud R, Garmy N, Maresca M, Yahi N, Puigserver A, Fantini J. Identification of a common sphingolipid-binding domain in Alzheimer, prion, and HIV-1 proteins. J Biol Chem. 2002;277:11292-11296. (Pubitemid 34952893)
19. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature. 1984;312:763-767.
20. Alkhatib G, Combadiere C, Broder CC, et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV- 1. Science. 1996;272:1955-1958. (Pubitemid 26234510)
21. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 1996;272:872-877.
22. Nehete PN, Vela EM, Hossain MM, et al. A post-CD4-binding step involving interaction of the V3 region of viral gp120 with host cell surface glycosphingolipids is common to entry and infection by diverse HIV-1 strains. Antiviral Res. 2002;56:233-251.
23. Rawat SS, Viard M, Gallo SA, Rein A, Blumenthal R, Puri A. Modulation of entry of enveloped viruses by cholesterol and sphingolipids [Review]. Mol Membr Biol. 2003;20:243-254. (Pubitemid 37046249)
24. Puri A, Hug P, Jernigan K, Rose P, Blumenthal R. Role of glycosphingolipids in HIV-1 entry: requirement of globotriosylceramide (Gb3) in CD4/CXCR4-dependent fusion. Biosci Rep. 1999;19:317-325.
25. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry's disease: ceramidetrihexosidase deficiency. N Engl J Med. 1967;276:1163-1167.
26. Lund N, Branch DR, Sakac D, et al. Lack of susceptibility of cells from patients with Fabry disease to productive infection with R5 human immunodeficiency virus. AIDS. 2005;19:1543-1546. (Pubitemid 41400702)
27. Lund N, Branch DR, Mylvaganam M, et al. A novel soluble mimic of the glycolipid, globotriaosyl ceramide inhibits HIV infection. AIDS. 2006;20:333-343.
28. Fantini J, Tamalet C, Hammache D, Tourres C, Duclos N, Yahi N. HIV-1-induced perturbations of glycosphingolipid metabolism are cell-specific and can be detected at early stages of HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19:221-229. (Pubitemid 28489743)
29. Ramkumar S, Sakac D, Binnington B, Branch DR, Lingwood CA. Induction of HIV-1 resistance: cell susceptibility to infection is an inverse function of globotriaosyl ceramide levels. Glycobiology. 2009;19:76-82.
30. Yousefi S, Ma XZ, Singla R, et al. HIV-1 infection is facilitated in T cells by decreasing p56lck protein tyrosine kinase activity. Clin Exp Immunol. 2003;133:78-90. (Pubitemid 36791945)
31. Branch DR, Valenta LJ, Yousefi S, et al. VPAC1 is a cellular neuroendocrine receptor expressed on T cells that actively facilitates productive HIV-1 infection. AIDS. 2002;16:309-319. (Pubitemid 34165361)
32. Bokaei PB, Ma XZ, Sakac D, Branch DR. HIV-1 integration is inhibited by stimulation of the VPAC2 neuroendocrine receptor. Virology. 2007;362:38-49. (Pubitemid 46617687)
33. Mattocks M, Bond M, Bagovitch M, et al. Treatment of the neutral glycosphingolipid lysosomal storage disease via inhibition of the ABC drug transporter, MDR1: cyclosporine A can lower serum and liver globotriaosyl ceramide levels in the Fabry mouse model. FEBS J. 2006;273:2064-2075.
34. Nutikka A, Binnington-Boyd B, Lingwood CA. Methods for the identification of host receptors for Shiga toxin. In: Philpot D, Ebel F, eds. Methods in Molecular Medicine, vol. 73, E. Coli Shiga Toxin Methods and Protocols. Totowa, NY: Humana Press; 2003;197-208.
35. Cayer MP, Drouin M, Sea SP, et al. Comparison of promoter activities for efficient expression into human B cells and haematopoietic progenitors with adenovirus Ad5/F35. J Immunol Methods. 2007;322:118-127. (Pubitemid 46560590)
36. Nilsson M, Ljungberg J, Richter J, et al. Development of an adenoviral vector system with adenovirus serotype 35 tropism: efficient transient gene transfer into primary malignant hematopoietic cells. J Gene Med. 2004;6:631-641. (Pubitemid 40228079)
37. GenBank, Kojima et al. http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db= nuccore&id=7959010. Accessed June 12, 2002.
38. Lee L, Abe A, Shayman JA. Improved inhibitors of glucosylceramide synthase. J Biol Chem. 1999;274:14662-14669.
39. Puri A, Rawat SS, Lin HM, et al. An inhibitor of glycosphingolipid metabolism blocks HIV-1 infection of primary T cells. AIDS. 2004;18:849-858. (Pubitemid 38553705)
40. Kiguchi K, Henning-Chubb CB, Huberman E. Glycosphingolipid patterns of peripheral blood lymphocytes, monocytes, and granulocytes are cell specific. J Biochem. 1990;107:8-14. (Pubitemid 20027260)
41. Kniep B, Monner DA, Schwulera U, Muhlradt PF. Glycosphingolipids of the globo-series are associated with the monocytic lineage of human myeloid cells. Eur J Biochem. 1985;149:187-191. (Pubitemid 15013500)
42. Fletcher KS, Bremer EG, Schwarting GA. P blood group regulation of glycosphingolipid levels in human erythrocytes. J Biol Chem. 1979;254:11196-11198. (Pubitemid 10136129)
43. Liao Z, Cimakasky LM, Hampton R, Nguyen DH, Hildreth JE. Lipid rafts and HIV pathogenesis: host membrane cholesterol is required for infection by HIV type 1. AIDS Res Hum Retroviruses. 2001;17:1009-1019. (Pubitemid 32881320)
44. Kozak SL, Heard JM, Kabat D. Segregation of CD4 and CXCR4 into distinct lipid microdomains in T lymphocytes suggests a mechanism for membrane destabilization by human immunodeficiency virus. J Virol. 2002;76:1802-1815. (Pubitemid 34094628)
45. Nguyen DH, Giri B, Collins G, Taub DD. Dynamic reorganization of chemokine receptors, cholesterol, lipid rafts, and adhesion molecules to sites of CD4 engagement. Exp Cell Res. 2005;304:559-569. (Pubitemid 40321132)
46. Xiao L, Owen SM, Goldman I, et al. CCR5 coreceptor usage of non-syncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: delineation of consensus motif in the V3 domain that predicts CCR-5 usage. Virology. 1998;240:83-92. (Pubitemid 28394126)
47. Sakaida H, Hori T, Yonezawa A, et al. T-tropic human immunodeficiency virus type 1 (HIV-1)-derived V3 loop peptides directly bind to CXCR-4 and inhibit T-tropic HIV-1 infection. J Virol. 1998;72:9763-9770. (Pubitemid 28520841)
48. Delezay O, Hammache D, Fantini J, Yahi N. SPC3, a V3 loop-derived synthetic peptide inhibitor of HIV-1 infection, binds to cell surface glycosphingolipids. Biochemistry. 1996;35:15663-15671. (Pubitemid 26422303)
49. Fantini J, Hammache D, Piéroni G, Yahi N. Role of glycosphingolipid microdomains in CD4-dependent HIV-1 fusion. Glycoconj J. 2000;17:199-204. (Pubitemid 32055906)
50. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 1998;393:648-659. (Pubitemid 28289647)
51. Kanari Y, Clerici M, Abe H, et al. Genotypes at chromosome 22q12-13 are associated with HIV-1-exposed but uninfected status in Italians. AIDS. 2005;19:1015-1024. (Pubitemid 40961141)
52. Liu XH, Lingwood CA, Ray PE. Recruitment of renal tublular epithelial cells expressing verotoxin-1 (Stx1) receptors in HIV-1 transgenic mice with renal disease. Kidney Int. 1999;55:554-561.